Email this article Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer (Russian Translation of Cochrane Plain Language Summary)
- Issue: Vol 24, No 1 (2022)
- Pages: 134-134
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/106975
- DOI: https://doi.org/10.26442/18151434.2022.1.201513
- ID: 106975
Cite item
Full Text
Abstract
This publication is the Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review: Chuai Y, Rizzuto I, Zhang X, Li Y, Dai G, Otter SJ, Bharathan R, Stewart A, Wang A; Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer; Version published: 04 March 2021; DOI: 10;1002/14651858;CD013348;pub2
Keywords
angiogenesis Inhibitors, antineoplastic agents, bevacizumab, bias, brachytherapy, combined modality therapy, confidence intervals, gastric fistula, gastrointestinal hemorrhage, hypertension, indazoles, intestinal fistula, intestinal perforation, lapatinib, neoplasm recurrence local, progression-free survival, pyridines, pyrimidines, quality of life, quinazolines, randomized controlled trials as topic, sulfonamides, thromboembolism, uterine cervical neoplasms, vascular endothelial growth factor A
Full Text
##article.viewOnOriginalSite##
